Roivant Sciences Ltd (NAS:ROIVW)
$ 2.75 -0.11 (-3.85%) Market Cap: - Enterprise Value: - PE Ratio: 2.09 PB Ratio: 1.58 GF Score: 60/100

Roivant Sciences Ltd at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 10, 2022 / 07:15PM GMT
Tessa Thomas Romero
JPMorgan Chase & Co, Research Division - Associate

Welcome, everyone, to the 40th Annual JPMorgan Healthcare Conference. My name is Tessa Romero. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Taylor Hanley from the team.

Our next presenting company is Roivant. And presenting on behalf of the company, we have CEO, Matthew Gline. Before I turn it over to Matthew, I just wanted to highlight to all of our listeners to please use the ask a question feature in the portal to ask any of your questions, and I'll get it in on your behalf. With that, I'd like to hand it over to you, Matthew.

Matthew Gline
Roivant Sciences Ltd. - CEO & Director

Thank you. Appreciate it, and good afternoon, everybody. Thank you for having me at the conference. I'm going to start today with a presentation outlining a little bit about Roivant and some of the things we're working on, and then we'll end with some time for Q&A. So thank you very much.

I think the slides are self advanced, so I'll call out slide

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot